the next reporting period is key to whether this stock will drop to 0.02 stock. management needs to demonstrate the company is making a profit and also growth. again, management has their own agenda and the comparative risk leads them to choose short term gain (paying themselves well) and long term gain (becoming a leading researcher in pain treatment). there is no reason to believe otherwise unless management is willing to buy themselves but so far none of the management is doing so. this is a clear tell tale. this is such a sad story as this company would have a reasonable chance if they just focus on shareholder's interest by marketing their priced product. instead, they want more on their plate so that the management scientists are in a win win situation. very sad.